---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-010775"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2024-01-19T23:59:59+00:00"
generated_at: "2026-06-06T21:26:27.190035+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics reports $32.6M cash at Dec 31, 2023; receives $7.5M from Dr. Reddy's in Jan 2024

## Summary
- Cash and equivalents $32.6M as of Dec 31, 2023; pro forma $40.1M after $7.5M received from Dr. Reddy's in Jan 2024.
- Milestone payments: $4.2M upon FDA acceptance of IND for COYA 302 (ALS) and $4.2M upon first patient dosed in Phase 2.
- Anticipates IND filing in H1 2024 and first patient dosing in H2 2024 for COYA 302 in ALS.
- Company expects current cash runway to fund operations into 2026.

## SEC filing metadata
- accession: 0001193125-24-010775
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2024-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312524010775/0001193125-24-010775-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312524010775/d732822d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-010775
- JSON: https://secwatch.observer/filing/0001193125-24-010775.json
- Plain text: https://secwatch.observer/filing/0001193125-24-010775.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.